Ittigen And Bern

Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study

Older News

ITTIGEN and BERN, Switzerland, November 11, 2010 - Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC).

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy